GSA Capital Partners LLP Reduces Position in DURECT Co. (NASDAQ:DRRX)

GSA Capital Partners LLP decreased its holdings in DURECT Co. (NASDAQ:DRRX) by 86.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 41,790 shares of the specialty pharmaceutical company’s stock after selling 257,715 shares during the period. GSA Capital Partners LLP’s holdings in DURECT were worth $56,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Richmond Brothers Inc. grew its stake in DURECT by 39.5% in the 2nd quarter. Richmond Brothers Inc. now owns 1,072,014 shares of the specialty pharmaceutical company’s stock valued at $1,383,000 after buying an additional 303,670 shares in the last quarter. Accredited Investors Inc. bought a new position in shares of DURECT in the second quarter worth $113,000. Finally, International Assets Investment Management LLC boosted its holdings in shares of DURECT by 41.3% in the second quarter. International Assets Investment Management LLC now owns 21,550 shares of the specialty pharmaceutical company’s stock worth $28,000 after acquiring an additional 6,300 shares during the period. Institutional investors own 28.03% of the company’s stock.

Analysts Set New Price Targets

DRRX has been the topic of a number of analyst reports. StockNews.com initiated coverage on DURECT in a research note on Tuesday, November 19th. They set a “sell” rating on the stock. HC Wainwright reiterated a “neutral” rating on shares of DURECT in a research report on Thursday, November 14th.

DURECT Price Performance

DRRX opened at $0.97 on Tuesday. The firm has a market capitalization of $30.11 million, a P/E ratio of -1.59 and a beta of 1.13. DURECT Co. has a one year low of $0.48 and a one year high of $1.88. The company has a fifty day moving average price of $1.28 and a 200-day moving average price of $1.36.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.